# GLG1

## Overview
The GLG1 gene encodes Golgi glycoprotein 1, a type I transmembrane sialoglycoprotein predominantly located in the Golgi apparatus of human cells. This protein is integral to the cell secretory pathway, functioning as a ligand for E-selectin and a receptor for various fibroblast growth factors (FGFs), thereby playing a pivotal role in cell adhesion, mobility, and migration (Antonenko2020Interaction). GLG1 is characterized by its complex structure, which includes multiple cysteine-rich repeats and a transmembrane domain, and undergoes significant post-translational modifications such as N-glycosylation, essential for its stability and function (Yamaguchi2022Antitumor). The gene is subject to alternative splicing, resulting in different isoforms that can influence the protein's localization and function (Ahn2005A). GLG1's interactions and regulatory roles in cellular processes have significant implications in various diseases, including cancer, where it may act as a decoy receptor modulating growth factor activity (Yamaguchi2022Antitumor).

## Structure
The GLG1 protein, also known as Golgi glycoprotein 1, is a type I membrane protein primarily located in the Golgi apparatus. It is characterized by a molecular structure that includes 16 cysteine-rich repeats in its extracellular luminal amino-terminal region, a 21 amino acid transmembrane domain, and a 13 amino acid intracellular cytoplasmic carboxy-terminal domain (Yamaguchi2022Antitumor). The protein undergoes post-translational modifications such as N-glycosylation, which are essential for its function and stability (Ahn2005A).

Alternative splicing of the GLG1 gene results in different isoforms, including GLG2, which has an additional 24 amino acids in its C-terminal domain compared to GLG1 (Ahn2005A). Other splice variants include variant 2, which lacks an internal segment, and variant 3, which has a shorter C-terminus due to an additional segment in the 3' region (Yamaguchi2022Antitumor). These isoforms can affect the protein's localization and function, with GLG1 primarily associated with the Golgi complex and GLG2 having a distinct intracellular localization pattern (Ahn2005A).

## Function
The GLG1 gene encodes Golgi glycoprotein 1, a membrane sialoglycoprotein primarily located in the Golgi apparatus of human cells. This protein plays a crucial role in the cell secretory pathway, interacting with various proteins and acting as a ligand for E-selectin and a receptor for several fibroblast growth factors (FGFs) (Antonenko2020Interaction). GLG1 is involved in cell adhesion, mobility, and migration, and its inhibition can alter the architecture of the Golgi complex, decrease integrin β1 protein levels, and reduce tumor cell migration (Antonenko2020Interaction).

GLG1 functions as a 'decoy receptor' for FGFs, binding them efficiently without signaling or activating the intended receptor complex. This binding regulates intracellular FGF levels, which are essential for cellular processes such as growth, motility, differentiation, and metabolism (Yamaguchi2022Antitumor). The protein is also implicated in the trafficking of leukocytes through the vascular endothelium, acting as an adhesive interaction molecule with selectin family receptors (Ahn2005A).

In the Golgi complex, GLG1 may act as a chaperone necessary for growth factor functions, although its precise role in healthy cells is not fully understood (Antonenko2020Interaction). The protein's expression and N-glycosylation are necessary to generate a high-affinity binding site between E-selectin and cells (Ahn2005A).

## Clinical Significance
The GLG1 gene, also known as Golgi glycoprotein 1, plays a significant role in various diseases due to its involvement in cellular processes such as protein trafficking and signaling. Alterations in GLG1 expression have been linked to cancer, particularly glioma and breast cancer. Studies have shown that GLG1 acts as a decoy receptor for fibroblast growth factors (FGFs), and its altered expression can modulate cancer cell proliferation. Treatment with memantine, a drug primarily used for Alzheimer's disease, has been found to increase the expression of GLG1 variants, which may contribute to its antitumor effects by downregulating FGF levels and reducing tumor cell proliferation (Yamaguchi2022Antitumor).

In chronic myeloid leukemia (CML), GLG1 interacts with the Bcr-Abl oncoprotein, a fusion protein with constitutive tyrosine kinase activity. This interaction occurs in the Golgi complex and involves the phosphorylation of GLG1, potentially disrupting signaling pathways crucial for CML progression. The interaction between GLG1 and Bcr-Abl may affect cell mobility, migration, and adhesion, contributing to the spread of undifferentiated cells and the progression of CML (Antonenko2020Interaction). These findings suggest that GLG1's interactions and expression levels are critical in the pathogenesis of certain cancers.

## Interactions
GLG1, also known as Golgi glycoprotein 1, is involved in several protein interactions that influence cellular processes. In the context of chronic myeloid leukemia (CML), GLG1 interacts with the Bcr-Abl oncoprotein. This interaction occurs specifically with the pleckstrin homology (PH) domain of Bcr-Abl and has been confirmed through co-immunoprecipitation and Western blot analysis. The interaction leads to the phosphorylation of GLG1 by Bcr-Abl, which affects GLG1's activity and disrupts signaling pathways crucial for CML progression (Antonenko2020Interaction).

GLG1 also serves as a ligand for E-selectin and a receptor for fibroblast growth factors (FGFs), indicating its role in cell signaling and adhesion. The protein's luminal domain is involved in binding with broad specificity to proteins such as FGF, E-selectin, and latent TGF-β complex, which may be crucial for its localization and function within the Golgi complex (Ahn2005A).

Additionally, GLG1 is implicated in the retrieval of proteins from late endosomes to the Golgi apparatus, interacting with the AP-5 adaptor protein complex. This interaction is part of a broader network of protein sorting and trafficking within the cell (Hirst2018Role).


## References


[1. (Hirst2018Role) Jennifer Hirst, Daniel N. Itzhak, Robin Antrobus, Georg H. H. Borner, and Margaret S. Robinson. Role of the ap-5 adaptor protein complex in late endosome-to-golgi retrieval. PLOS Biology, 16(1):e2004411, January 2018. URL: http://dx.doi.org/10.1371/journal.pbio.2004411, doi:10.1371/journal.pbio.2004411. This article has 107 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pbio.2004411)

[2. (Ahn2005A) Jongcheol Ahn, Maria Febbraio, and Roy L. Silverstein. A novel isoform of human golgi complex-localized glycoprotein-1 (also known as e-selectin ligand-1, mg-160 and cysteine-rich fibroblast growth factor receptor) targets differential subcellular localization. Journal of Cell Science, 118(8):1725–1731, April 2005. URL: http://dx.doi.org/10.1242/jcs.02310, doi:10.1242/jcs.02310. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.02310)

[3. (Antonenko2020Interaction) S. V. Antonenko, I. V. Kravchuk, and G. D. Telegeev. Interaction of bcl-abl oncoprotein with the glg1 protein in k562 cells: its role in the pathogenesis of chronic myeloid leukemia. Cytology and Genetics, 54(1):48–54, January 2020. URL: http://dx.doi.org/10.3103/S0095452720010028, doi:10.3103/s0095452720010028. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3103/S0095452720010028)

[4. (Yamaguchi2022Antitumor) Fumio Yamaguchi, Sumio Hayakawa, Shota Kawashima, Takayuki Asakura, and Yumiko Oishi. Antitumor effect of memantine is related to the formation of the splicing isoform of glg1, a decoy fgf‑binding protein. International Journal of Oncology, May 2022. URL: http://dx.doi.org/10.3892/ijo.2022.5370, doi:10.3892/ijo.2022.5370. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2022.5370)